Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose naltrexone for fibromyalgia
ACTRN12623000172606Phase 2Recruiting
- Sponsor
- The University of Queensland
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of naltrexone in fibromyalgia (FM) (2 arms), sponsored by The University of Queensland. Primary endpoint: Pain severity at 12 weeks. Started Nov 2024; status: recruiting.
02
Drugs
naltrexone
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on ACTRN12623000172606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000172606.